Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04304105 · ClinicalTrials.gov registry record
Natural Progression of High-Risk Chronic Limb-Threatening Ischemia: The CLariTI Study
A clinical trial, sponsored by LimFlow.
- Completed
- Registry status
- 192
- Enrollment target
NCT04304105: Completed study, sponsored by LimFlow.
NCT04304105 is a clinical trial that has completed, run by LimFlow. The registered enrollment target is 192 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04304105 has completed, sponsored by LimFlow.
- COMPLETED
- Registry status
- 192 participants
- Enrollment target
Study Summary
The objective of this observational registry is to track the clinical progression of chronic limb-threatening ischemia (CLTI) and incidence of death, amputation, and revascularization attempts over a one-year period.
Primary Outcome
Defined as freedom from major (above ankle) amputation and death
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2020-02-24 |
| Est. Completion | 2022-09-12 |
What the finished NCT04304105 record still lists
NCT04304105 is an observational study that tracks outcomes without assigning an intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04304105 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04304105 about?
NCT04304105 is a clinical study titled "Natural Progression of High-Risk Chronic Limb-Threatening Ischemia: The CLariTI Study". The objective of this observational registry is to track the clinical progression of chronic limb-threatening ischemia (CLTI) and incidence of death, amputation, and revascularization attempts over a one-year period.
What is the current status of trial NCT04304105?
This trial is currently completed. The enrollment target is 192 participants. The study started on 2020-02-24. Estimated completion is 2022-09-12.
Who is sponsoring clinical trial NCT04304105?
This trial is sponsored by LimFlow, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI